Trial Profile
A Multi-center, Randomized, Double-blind, Parellel Group Trial Compares the Efficacy and Safety of Fixed-dose Rosiglitazone/Glimepiride Combination (FDC) Therapy to Uptitrated Glimepiride Monotherapy for 24 Weeks in Drug Naive T2DM Patients.
Status:
Discontinued
Phase of Trial:
Phase III
Latest Information Update: 26 Aug 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone/glimepiride (Primary) ; Glimepiride
- Indications Type 2 diabetes mellitus
- Focus Therapeutic Use
- Acronyms AVY CHN 1 Line
- Sponsors GlaxoSmithKline; GSK
- 19 Oct 2011 New trial record